Switch theme
Sign up to access all valuation multiples
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.
1997
40
LTM Revenue $6.1M
LTM EBITDA n/a
$14.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Starpharma has a last 12-month revenue of $6.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Starpharma achieved revenue of $5.2M and an EBITDA of -$6.1M.
Starpharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Starpharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.8M | $5.2M | XXX | XXX | XXX |
| Gross Profit | $1.2M | $1.1M | XXX | XXX | XXX |
| Gross Margin | 65% | 22% | XXX | XXX | XXX |
| EBITDA | -$10.7M | -$6.1M | XXX | XXX | XXX |
| EBITDA Margin | -580% | -116% | XXX | XXX | XXX |
| Net Profit | -$10.2M | -$9.8M | XXX | XXX | XXX |
| Net Margin | -550% | -189% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Starpharma's stock price is AUD 0 (or $0).
Starpharma has current market cap of AUD 41.0M (or $25.8M), and EV of AUD 23.2M (or $14.6M).
See Starpharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.6M | $25.8M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Starpharma has market cap of $25.8M and EV of $14.6M.
Starpharma's trades at 2.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Starpharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Starpharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $14.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpStarpharma's NTM/LTM revenue growth is -100%
Starpharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Starpharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Starpharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Starpharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 182% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -43% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 43% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 121% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 222% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Starpharma acquired XXX companies to date.
Last acquisition by Starpharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Starpharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Starpharma founded? | Starpharma was founded in 1997. |
| Where is Starpharma headquartered? | Starpharma is headquartered in Australia. |
| How many employees does Starpharma have? | As of today, Starpharma has 40 employees. |
| Is Starpharma publicy listed? | Yes, Starpharma is a public company listed on ASX. |
| What is the stock symbol of Starpharma? | Starpharma trades under SPL ticker. |
| When did Starpharma go public? | Starpharma went public in 2000. |
| Who are competitors of Starpharma? | Similar companies to Starpharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Starpharma? | Starpharma's current market cap is $25.8M |
| What is the current revenue of Starpharma? | Starpharma's last 12-month revenue is $6.1M. |
| What is the current EV/Revenue multiple of Starpharma? | Current revenue multiple of Starpharma is 2.4x. |
| What is the current revenue growth of Starpharma? | Starpharma revenue growth between 2023 and 2024 was 182%. |
| Is Starpharma profitable? | Yes, Starpharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
